FDA Approves Cabozantinib for Hepatocellular Carcinoma

Approval is based on results from the CELESTIAL trial
16 Jan 2019

On 14 January 2019, the US Food and Drug Administration (FDA) approved cabozantinib (CABOMETYX, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Approval was based on CELESTIAL (NCT01908426), a randomised (2:1), double-blind, placebo-controlled, multicentre trial in patients with HCC who had previously received sorafenib and had Child Pugh Class A liver impairment. Patients were randomised to receive cabozantinib 60 mg orally once daily (n=470) or placebo (n=237) until disease progression or unacceptable toxicity.

The primary efficacy measure was overall survival (OS); additional outcome measures were progression-free survival (PFS) and overall response rate (ORR), as assessed by investigators per RECIST v1.1. Median OS was 10.2 months (95% CI: 9.1,12.0) for patients receiving cabozantinib and 8 months (95% CI: 6.8, 9.4) for those receiving placebo (HR 0.76; 95% CI: 0.63, 0.92; p = 0.0049). Median PFS was 5.2 months (4.0, 5.5) and 1.9 months (1.9, 1.9), in the cabozantinib and placebo arms, respectively (HR 0.44; 95% CI: 0.36, 0.52; p < 0.001). The ORR was 4% (95% CI: 2.3, 6.0) in the cabozantinib arm and 0.4% (95% CI: 0.0, 2.3) in the placebo arm.

The most common adverse reactions in ≥ 25% of patients who received cabozantinib in clinical trials, in order of decreasing frequency, are diarrhoea, fatigue, decreased appetite, palmar-plantar erythrodysesthesia, nausea, hypertension, and vomiting.

The recommended cabozantinib dose is 60 mg orally, once daily at least one hour before or 2 hours after eating.

Full prescribing information for CABOMETYX is available here.

FDA granted this application orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 16 Jan 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings